Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Infect Dis ; 183(6): 880-6, 2001 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-11237804

RESUMO

Antibiotic-resistant pneumococci are difficult to eradicate from middle ear fluid (MEF) and the nasopharynx (NP). Bacteriologic eradication from the NP and MEF during acute otitis media (AOM) by 3 common antibiotic drugs was prospectively evaluated. In 19 (16%) of 119 MEF culture-positive patients, an organism susceptible to the treatment drug (Haemophilus influenzae, Streptococcus pneumoniae, or both) was isolated from the initial MEF, whereas resistant S. pneumoniae was present in the NP; in 9 (47%) patients, the initial resistant NP organism (identified by serotyping, resistance to the administered drug, and pulsed-field gel electrophoresis) replaced the susceptible MEF organism within only a few days after initiation of treatment. In regions where resistant pneumococci are prevalent, antibiotics may not only fail to eradicate the organisms, but they may often induce MEF superinfection with resistant pneumococci initially carried in the NP. This is an important mechanism by which, in recently treated patients, AOM infections often become refractory to treatment.


Assuntos
Resistência Microbiana a Medicamentos , Otite Média/tratamento farmacológico , Infecções Pneumocócicas/tratamento farmacológico , Streptococcus pneumoniae/efeitos dos fármacos , Superinfecção/tratamento farmacológico , Doença Aguda , Combinação Amoxicilina e Clavulanato de Potássio/uso terapêutico , Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Criança , Quimioterapia Combinada/uso terapêutico , Orelha Média/microbiologia , Feminino , Humanos , Masculino , Nasofaringe/microbiologia , Otite Média/microbiologia , Infecções Pneumocócicas/microbiologia , Sorotipagem , Streptococcus pneumoniae/isolamento & purificação , Superinfecção/microbiologia , Fatores de Tempo , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA